The bills aim to address the perceived perverse incentives in the PBM industry, such as steering patients to mail-order pharmacies that benefit the PBMs financially, leading to higher costs for consumers.
The legislation would force companies that own both insurers and PBMs to sell off their pharmacy businesses, including retail, mail-order, and specialty pharmacies, affecting major players like CVS Health, Cigna, and UnitedHealth Group.
PBMs create formularies, prioritize drugs for specific diseases, and negotiate discounts and rebates on drugs, aiming to save employers and consumers money by securing better deals on medications.
If passed, the legislation could end practices like steering patients to mail-order pharmacies that benefit PBMs financially, potentially reducing costs for consumers and eliminating conflicts of interest.
The bipartisan support suggests growing interest in addressing healthcare costs and populist concerns, increasing the likelihood that Congress may finally pass significant PBM reform legislation.
The consumer price index rose 2.7% year-over-year and 0.3% month-over-month, marking the strongest monthly increase since April, driven by higher vehicle prices and persistent inflation in housing and services.
The data shows persistent inflation, particularly in services, which the Fed has been trying to contain. While the trend is encouraging, the Fed will monitor rising goods prices, which could complicate their efforts to bring inflation back to target.
Coffee prices, particularly for Arabica beans, have surged due to severe droughts and heavy rains in Brazil, the largest exporter of Arabica, and reduced production in Vietnam, the largest Robusta producer, leading to supply concerns.
P.M. Edition for Dec. 11. Bills introduced) in the Senate and House seek to break up pharmacy-benefit managers, or PBMs. WSJ reporter Liz Essley Whyte) explains what that could mean for companies and for consumers. And U.S. inflation ticked up last month). Wall Street Journal economics reporter Harriet Torry) clues us in on what that might mean for the Fed when it meets next week. Plus, FBI Director Christopher Wray steps down) before President-elect Donald Trump takes office. Alex Ossola hosts.
Sign up for the WSJ's free What's News newsletter).
Learn more about your ad choices. Visit megaphone.fm/adchoices)